Welcome to our dedicated page for Scholar Rock Holding SEC filings (Ticker: SRRK), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Scholar Rock Holding's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Scholar Rock Holding's regulatory disclosures and financial reporting.
Scholar Rock Holding Corporation files its annual report describing a biopharmaceutical business focused on rare neuromuscular diseases, especially spinal muscular atrophy (SMA) and facioscapulohumeral muscular dystrophy (FSHD).
The company’s lead antibody, apitegromab, showed positive Phase 3 SAPPHIRE results in SMA, supporting improved motor function on top of existing SMN-targeted therapies. A biologics license application received FDA priority review but then a complete response letter tied to a third-party fill‑finish facility; the company plans to resubmit after cGMP issues at that facility are resolved. An EMA marketing application for apitegromab has been validated.
Scholar Rock reports a broad pipeline including subcutaneous apitegromab, SRK‑439 for neuromuscular diseases, SRK‑181 for solid tumors resistant to anti‑PD‑(L)1 therapy, and earlier programs such as SRK‑373 and SRK‑256. As of June 30, 2025, non‑affiliate common stock market value was about $2.6 billion, and as of February 26, 2026, 114,883,096 common shares were outstanding.
Scholar Rock Holding Corporation reported wider losses for the fourth quarter and full year 2025 while highlighting progress in its spinal muscular atrophy pipeline. Quarterly net loss was $90.965 million, compared with $66.454 million a year earlier, and full-year net loss was $377.939 million versus $246.294 million in 2024.
Operating expenses rose sharply, with 2025 research and development at $208.440 million and general and administrative at $176.205 million. Cash, cash equivalents and marketable securities totaled $367.563 million as of December 31, 2025, down from $437.278 million a year earlier.
The company emphasized advancing apitegromab for SMA, citing FDA engagement and readiness to resubmit its BLA after successful reinspection of Novo Nordisk’s Catalent Indiana facility. It also highlighted SRK-439, a preclinical myostatin inhibitor, and described 2026 as potentially “transformative” as it continues to invest heavily in its neuromuscular disease portfolio.
Scholar Rock Holding Corp’s chief scientific officer, Mo Qatanani, sold a total of 8,484 shares of common stock in open‑market transactions on February 23, 2026. The sales were executed under a pre‑established Rule 10b5‑1 trading plan adopted on March 31, 2025.
The transactions were split into three tranches: 7,427 shares at a weighted average price of $46.9422, 857 shares at $47.8588, and 200 shares at $48.4800, with each tranche covering multiple trades within stated price ranges. Following these sales, Qatanani’s reported holdings consist of 98,445 RSUs.
Mohammed Qatanani filed a Form 144 reporting a proposed sale of 8,484 shares of Common stock related to a Restricted Stock Award dated 02/15/2026. The filing also lists prior sales of Common stock on 12/04/2025 (136,462), 01/14/2026 (13,112), and 01/22/2026 (14,898). The broker noted is J.P. Morgan Securities LLC.
Scholar Rock Holding Corp's chief medical officer, Jing L. Marantz, reported an open-market sale of 4,157 shares of common stock on February 17, 2026 at a price of $46.5282 per share. This transaction was executed to cover tax withholding obligations arising from the vesting of restricted stock units on February 15, 2026 and was mandated under the company’s equity incentive plan rather than being a discretionary trade.
After this sale, Marantz held 126,012 shares of common stock, consisting of 29,388 shares of common stock and 96,624 restricted stock units that continue to vest annually over four years, subject to continued service with the company.
Scholar Rock Holding Corp’s general counsel, Junlin Ho, reported an open-market sale of 9,580 shares of common stock on February 17, 2026 at an average price of $46.5282 per share. According to the footnote, this sale was a mandated “sell to cover” transaction to fund tax withholding arising from the vesting of restricted stock units (RSUs) on February 15, 2026, and was not a discretionary trade.
The RSUs that vested were granted on February 13, 2023 and March 10, 2025, each representing the right to receive one share of common stock upon vesting. After this tax-related sale, Ho’s holdings consist of 131,646 shares of common stock and 109,899 RSUs, which vest annually over four years, subject to a continued service relationship with the company.
Scholar Rock Holding Corp's CHRO, Caryn Parlavecchio, reported a mandatory sale of common stock tied to tax withholding on vested RSUs. On this Form 4, she sold 9,035 shares of common stock in an open-market transaction at an average price of $46.5282 per share to cover tax obligations from restricted stock units that vested on February 15, 2026. The footnote explains this was a required "sell to cover" transaction under the company’s equity incentive plans and not a discretionary trade. After the sale, she beneficially owns 169,087 equity-linked interests, consisting of 86,859 shares of common stock and 82,228 RSUs that continue to vest annually over four years, subject to continued service.
Scholar Rock Holding Corp’s Chief Scientific Officer Mo Qatanani reported an open-market sale of 7,989 shares of common stock at an average price of $46.5282 per share.
According to the footnotes, this was a mandated “sell to cover” transaction to satisfy tax withholding obligations arising from restricted stock units (RSUs) that vested on February 15, 2026, under the company’s equity incentive plans, and was not a discretionary trade. After this transaction, Qatanani’s reported holdings consist of 8,484 shares of common stock and 98,445 RSUs, which together total 106,929 units of equity-related interests.
Vaishnaw Akshay reported acquisition or exercise transactions in this Form 4 filing.
Scholar Rock Holding Corp reported that President of R&D and director Akshay Vaishnaw received a grant of 47,021 restricted stock units (RSUs) of common stock on February 9, 2026, at a stated price of $0.00 per share as a compensatory award.
Each RSU represents one share of common stock upon vesting and vests in four equal annual installments over four years, starting on January 15, 2027, contingent on continued service. After this grant, Vaishnaw directly holds 642,788 equity interests, consisting of 45,767 shares of common stock, 147,021 time-based RSUs, and 450,000 performance- and time-based RSUs.
Sinha Vikas reported acquisition or exercise transactions in this Form 4 filing.
Scholar Rock Holding Corp’s Chief Financial Officer Vikas Sinha received a grant of 47,021 restricted stock units on February 9, 2026 at a stated price of $0.00 per unit. These RSUs vest in four equal annual installments starting on January 15, 2027, as long as he remains in service. After this grant, he beneficially owns 630,266 equity-linked interests, consisting of 33,245 shares of common stock, 147,021 time-based RSUs, and 450,000 performance- and time-based RSUs.